MNG854
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.425
- HEDGEHOG_SIGNALING+0.259
- APICAL_SURFACE+0.238
- ANGIOGENESIS+0.234
- SPERMATOGENESIS+0.205
- MYOGENESIS+0.175
- XENOBIOTIC_METABOLISM+0.159
- ESTROGEN_RESPONSE_EARLY+0.145
- KRAS_SIGNALING_DN+0.142
- ESTROGEN_RESPONSE_LATE+0.135
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.514
- INTERFERON_GAMMA_RESPONSE-0.499
- INTERFERON_ALPHA_RESPONSE-0.464
- MYC_TARGETS_V2-0.446
- ALLOGRAFT_REJECTION-0.438
- IL6_JAK_STAT3_SIGNALING-0.431
- INFLAMMATORY_RESPONSE-0.427
- TGF_BETA_SIGNALING-0.379
- P53_PATHWAY-0.362
- CHOLESTEROL_HOMEOSTASIS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG891 | — | — | 0.856 |
| 2 | MNG825 | — | — | 0.841 |
| 3 | MNG35 | — | — | 0.836 |
| 4 | SRR1435484 | GTEX | — | 0.824 |
| 5 | SRR1331335 | GTEX | — | 0.823 |
| 6 | SRR1388378 | GTEX | — | 0.821 |
| 7 | SRR1336158 | GTEX | — | 0.817 |
| 8 | SRR1331751 | GTEX | — | 0.816 |
| 9 | SRR1500868 | GTEX | — | 0.815 |
| 10 | SRR1341277 | GTEX | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.425 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.259 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.238 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.234 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.205 | Inavolisib | — uncovered |
| MYOGENESIS | 0.175 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.159 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.145 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.142 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.135 | Idelalisib | — uncovered |
| PEROXISOME | 0.088 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.062 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.052 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.043 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.036 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.027 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.026 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.015 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.012 | Inavolisib | — uncovered |
| COAGULATION | 0.009 | Binimetinib | — uncovered |